X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net Proceeds will be used to advance the clinical development of the leading candidate, PTT-4256, currently undergoing early-stage evaluation for neoplasm treatment.
Lead Product(s): PTT-4256
Therapeutic Area: Oncology Product Name: PTT-4256
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 18, 2024
Details:
The grant funding will enable the company to expand its development of novel small molecule GPR65 inhibitors into the area of a possible treatment of malignant brain tumors.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: UK government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 27, 2023
Details:
Findings to showcase the promise of company's 'Macrophage Conditioning' approach in reversing immunosuppression within acidic tumor microenvironment and driving anti-tumor activity.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
In the research presented, Pathios evaluated the impact of PTT-3196, an orally bioavailable, potent and selective GPR65 inhibitor, on expression of key immune-related genes and tumor growth in a highly glycolytic RCC PDX model implanted in NCG mice.
Lead Product(s): PTT-3196
Therapeutic Area: Oncology Product Name: PTT-3196
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2021
Details:
Pathios Therapeutics will team up with researchers at The University of Oxford to accelerate cancer immunotherapies targeting GPR65 on immunosuppressive macrophages.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: $475.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
